Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
Swiss AviationSoftware is a 100% subsidiary of Lufthansa Technik, and along with our partners in the Digital Tech Ops Ecosystem (Swiss-AS, Aviatar, flydocs), we lead the digital transformation era within the Technical Operations aviation industry. To